

Lab No. : 283280071

A/c Status : P

Age: 50 Years

Ref By: Dr. SELF

Gender:

Male

Collected Received 30/6/2020 8:15:00AM

Reported

30/6/2020 11:39:35AM 30/6/2020 5:36:27PM

Report Status : Final

Test Name	Results	Units	Bio. Ref. Interval
SWASTHFIT SUPER 4 PACKAGE			
LIVER & KIDNEY PANEL, SERUM (Spectrophotometry, Indirect ISE)			
Bilirubin Total	0.60	mg/dL	0.30 - 1.20
Bilirubin Direct	0.13	mg/dL	<0.30
Bilirubin Indirect	0.47	mg/dL	<1.10
AST (SGOT)	25	U/L	<50
ALT (SGPT)	36	U/L	<50
GGTP	23	U/L	<55
Alkaline Phosphatase (ALP)	88	U/L	30 - 120
Total Protein	7.50	g/dL	6.40 - 8.30
Albumin	4.50	g/dL	3.50 - 5.20
A : G Ratio	1.50		0.90 - 2.00
Urea	25.10	mg/dL	17.00 - 43.00
Creatinine	0.78	mg/dL	0.67 - 1.17



Page 1 of 12



N	Name : Mr. DAVINDER	Collected : 30/6/2020 8:15:00AM
1	Lab No. : 283280071 Age: 50 Years Gender: Male	Received : 30/6/2020 11:39:35AM Reported : 30/6/2020 5:36:27PM
1	A/c Status : P Ref By : Dr. SELF	Report Status : Final Status Status Status

Test Name Uric Acid	Results 8.04	<b>Units</b> mg/dL	<b>Bio. Ref. Interval</b> 3.50 - 7.20
Calcium, Total	9.36	mg/dL	8.80 - 10.60
Phosphorus	3.10	mg/dL	2.40 - 4.40
Sodium	137.68	mEq/L	136.00 - 146.00
Potassium	3.96	mEq/L	3.50 - 5.10
Chloride	101.60	mEq/L	101.00 - 109.00





Name : Mr. DAVINDER

Lab No.

A/c Status

283280071 Age: 50 Years

Ref By: Dr. SELF

Male Gender:

Collected Received : 30/6/2020 8:15:00AM

30/6/2020 11:39:35AM : 30/6/2020 5:36:27PM Reported

Report Status Final

Test Name	Results	Units	Bio. Ref. Interval
COMPLETE BLOOD COUNT; CBC			
(Electrical Impedance & Flow)			
Hemoglobin	15.00	g/dL	13.00 - 17.00
Packed Cell Volume (PCV)	44.90	%	40.00 - 50.00
RBC Count	5.35	mill/mm3	4.50 - 5.50
MCV	83.90	fL	80.00 - 100.00
MCH	28.00	pg	27.00 - 32.00
MCHC	33.40	g/dL	32.00 - 35.00
Red Cell Distribution Width (RDW)	14.40	%	11.50 - 14.50
Total Leukocyte Count (TLC)	5.95	thou/mm3	4.00 - 10.00
Differential Leucocyte Count (DLC)			
Segmented Neutrophils	52.00	%	40.00 - 80.00
Lymphocytes	36.10	%	20.00 - 40.00
Monocytes	8.90	%	2.00 - 10.00
Eosinophils	2.00	%	1.00 - 6.00
Basophils	1.00	%	<2.00
Absolute Leucocyte Count			
Neutrophils	3.09	thou/mm3	2.00 - 7.00
Lymphocytes	2.15	thou/mm3	1.00 - 3.00
Monocytes	0.53	thou/mm3	0.20 - 1.00
Eosinophils	0.12	thou/mm3	0.02 - 0.50
Basophils	0.06	thou/mm3	0.01 - 0.10
Platelet Count	135.0	thou/mm3	150.00 - 450.00



Page 3 of 12



 Name
 Mr. DAVINDER
 Collected
 : 30/6/2020 8:15:00AM

 Lab No.
 : 283280071 Age: 50 Years
 Gender: Male
 Received Reported
 : 30/6/2020 5:36:27PM

A/c Status P Ref By : Dr. SELF Report Status : Final

Test Name	Results	Units	Bio. Ref. Interval
Platelets are mildly reduced  Advised:  Follow up and Review.  Result rechecked			
Mean Platelet Volume (MPV)	12.50	fL	6.50 - 12.00

#### Note

- As per the recommendation of International council for Standardization in Hematology, the differential leucocyte counts are additionally being reported as absolute numbers of each cell in per unit volume of blood
- 2. Test conducted on EDTA whole blood





 Name
 : Mr. DAVINDER
 Collected
 : 30/6/2020
 8:15:00AM

 Received
 : 30/6/2020
 11:39:35AM

 Lab No.
 : 283280071
 Age: 50 Years
 Gender: Male
 Reported
 : 30/6/2020
 5:36:27PM

A/c Status P Ref By : Dr. SELF Report Status : Final

Test Name	Results	Units	Bio. Ref. Interval
HbA1c (GLYCOSYLATED HEMOGLOBIN), BLC	OOD		
( 20)			
HbA1c	5.7	%	
Estimated average glucose (eAG)	117	mg/dL	

#### Interpretation

As per American Diabetes Association (ADA)				
Reference Group	HbA1c in %			
Non diabetic adults >=18 years	4.0 - 5.6			
At risk (Prediabetes)	5.7 - 6.4			
Diagnosing Diabetes	>= 6.5			
Therapeutic goals for glycemic   control	< 7.0			

## Note

- Since HbA1c reflects long term fluctuations in the blood glucose concentration, a diabetic patient who
  is recently under good control may still have a high concentration of HbA1c. Converse is true for a
  diabetic previously under good control but now poorly controlled
- Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life
  expectancy and no significant cardiovascular disease. In patients with significant complications of
  diabetes, limited life expectancy or extensive co-morbid conditions, targeting a goal of < 7.0 % may not
  be appropriate</li>
- 3. Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered, particularly when the A1C result does not correlate with the patient's blood glucose levels
- 4. In patients with HbA1c level between 7-8%, Glycemark (1,5 Anhydroglucitol) test may be done to identify those with more frequent and extreme hyperglycemic excursions

## Comments

HbA1C reflects average glycemia over approximately 3 months, the test is the major tool for assessing glycemic control and has strong predictive value for diabetes complications. Thus, HbA1C testing should be performed routinely in all patients with diabetes - at initial assessment and as part of continuing care.



Page 5 of 12



Name : Mr. DAVINDER

Lab No.

A/c Status

283280071 Age:

Age: 50 Years Gender:

Dr. SELF

Ref By:

Collected

: 30/6/2020 8:15:00AM

Received Reported : 30/6/2020 11:39:35AM : 30/6/2020 5:36:27PM

Report Status

Final

Test Name Results Units Bio. Ref. Interval

Male

Measurement approximately every 3 months determines whether patients' glycemic targets have been reached and maintained. The frequency of A1C testing should depend on the clinical situation, the treatment regimen, and the clinician's judgement.

## ADA Recommendations for HbA1c testing

- 1. Perform the A1C test at least two times a year in patients who are meeting treatment goals (and who have stable glycemic control)
- Perform the A1C test quarterly in patients whose therapy has changed or who are not meeting glycemic goals

Factors that Interfere with HbA1c Measurement: Hemoglobin variants, elevated fetal hemoglobin (HbF) and chemically modified derivatives of hemoglobin (e.g. carbamylated Hb in patients with renal failure) can affect the accuracy of HbA1c measurements

Factors that affect interpretation of HbA1c Results: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g., recovery from acute blood loss, hemolytic anemia, HbSS, HbCC, and HbSC) will falsely lower HbA1c test results regardless of the assay method used. Iron deficiency anemia is associated with higher HbA1c





Name Collected 30/6/2020 8:15:00AM : Mr. DAVINDER 30/6/2020 11:39:35AM Received : 283280071 Age: 50 Years Lab No. Gender: Male Reported 30/6/2020 5:36:27PM A/c Status Ref By: Dr. SELF **Report Status** 

Test Name	Results	Units	Bio. Ref. Interval
THYROID PROFILE,TOTAL, SERUM (ECLIA)			
T3, Total *	0.86	ng/mL	0.80 - 2.00
T4, Total *	5.62	ug/dL	5.10 - 14.10
TSH *	3.22	uIU/mL	0.27 - 4.20

## Note

- 1. TSH levels are subject to circadian variation, reaching peak levels between 2 4.a.m. and at a minimum between 6-10 pm. The variation is of the order of 50%, hence time of the day has influence on the measured serum TSH concentrations.
- 2. Recommended test for T3 and T4 is unbound fraction or free levels as it is metabolically active.
- 3. Physiological rise in Total T3 / T4 levels is seen in pregnancy and in patients on steroid therapy.

# **Clinical Use**

- · Primary Hypothyroidism
- Hyperthyroidism
- Hypothalamic Pituitary hypothyroidism
- Inappropriate TSH secretion
- Nonthyroidal illness
- Autoimmune thyroid disease
- · Pregnancy associated thyroid disorders
- · Thyroid dysfunction in infancy and early childhood

\* Not in NABL scope



Page 7 of 12



Name : Mr. DAVINDER

Lab No. : 283280071

A/c Status

3280071 Age: 50 Years

Ref By: Dr. SELF

Male

Gender:

Collected Received Reported 30/6/2020 8:15:00AM 30/6/2020 11:39:35AM

: 30/6/2020 11:39:39AN : 30/6/2020 5:36:27PM

Report Status : Final

Test Name	Results	Units	Bio. Ref. Interval
LIPID SCREEN, SERUM (Spectrophotometry)			
Cholesterol, Total	201.00	mg/dL	<200.00
Triglycerides	97.00	mg/dL	<150.00
HDL Cholesterol	52.63	mg/dL	>40.00
LDL Cholesterol, Calculated	128.97	mg/dL	<100.00
VLDL Cholesterol,Calculated	19.40	mg/dL	<30.00
Non-HDL Cholesterol	148	mg/dL	<130

## Interpretation

REMARKS	TOTAL CHOLESTEROL   in mg/dL	TRIGLYCERIDE   in mg/dL	LDL CHOLESTEROL   in mg/dL	NON HDL CHOLESTEROL     in mg/dL
Optimal	<200	<150	<100	<130
Above Optimal	-		100-129	130 - 159
Borderline High	200-239	150-199	130-159	160 - 189
High	>=240	200-499	160-189	190 - 219
Very High	-	>=500	>=190	>=220

## Note

- Measurements in the same patient can show physiological & analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL& LDL Cholesterol.
- 2. NLA-2014 recommends a complete lipoprotein profile as the initial test for evaluating cholesterol.



Page 8 of 12



Name : Mr. DAVINDER

Lab No.

283280071

ERMANIANA IN INC MANIANA IN INC MANIANA IN Unika Du Lad PastiLaka Du Lad PastiLaka Du Lad P

Age: 50 Years

Collected Received : 30/6/2020 8:15:00AM : 30/6/2020 11:39:35AM

Reported : 30/6/2020 5:36:27PM

A/c Status : P Ref By : Dr. SELF Report Status : Final

Test Name Results Units Bio. Ref. Interval

Male

Friedewald equation to calculate LDL cholesterol is most accurate when Triglyceride level is < 400 mg/dL. Measurement of Direct LDL cholesterol is recommended when Triglyceride level is > 400 mg/dL

Gender:

- NLA-2014 identifies Non HDL Cholesterol(an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants)along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non HDL.
- 5. Apolipoprotein B is an optional, secondary lipid target for treatment once LDL & Non HDL goals have been achieved
- 6. Additional testing for Apolipoprotein B, hsCRP,Lp(a ) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

## Treatment Goals as per Lipid Association of India 2016

RISK CATEGORY			CONSI	DER THERAPY
CATEGORY	LDL CHOLESTEROL (LDL-C)(mg/dL)	NON HDL CHLOESTEROL (NON HDL-C) (mg/dL)	LDL CHOLESTEROL (LDL-C)(mg/dL)	NON HDL CHLOESTEROL   (NON HDL-C) (mg/dL)
Very   High	<50 		>=50	>=80
High	<70	<100	>=70	>=100
Moderate	<100	<130	>=100	>=130
Low	<100	<130	>=130*	>=160*

\*In low risk patient, consider therapy after an initial non-pharmacological intervention for at least 3 months





Name : Mr. DAVINDER

Lab No. : 283280071 A

Age: 50 Years

Dr. SELF

Ref By:

Male

Received Reported : 30/6/2020 8:15:00AM : 30/6/2020 11:39:35AM

: 30/6/2020 5:36:27PM

Report Status : Final

Test Name	Results	Units	Bio. Ref. Interval
VITAMIN B12; CYANOCOBALAMIN, SERUM *	225.60	pg/mL	197.00 - 771.00
(FCLIA)			

Gender:

#### **Notes**

A/c Status

- 1. Interpretation of the result should be considered in relation to clinical circumstances.
- It is recommended to consider supplementary testing with plasma Methylmalonic acid (MMA) or
  plasma homocysteine levels to determine biochemical cobalamin deficiency in presence of clinical
  suspicion of deficiency but indeterminate levels. Homocysteine levels are more sensitive but MMA is
  more specific
- 3. The concentration of Vitamin B12 obtained with different assay methods cannot be used interchangeably due to differences in assay methods and reagent specificity

## Comments

Vitamin B12 performs many important functions in the body, but the most significant function is to act as co-enzyme for reducing ribonucleotides to deoxyribonucleotides, a step in the formation of genes. Inadequate dietary intake is not the commonest cause for cobalamine deficiency. The most common cause is malabsorption either due to atrophy of gastric mucosa or diseases of terminal ileum. Cobalamine deficiency leads to Megaloblastic anemia and demyelination of large nerve fibres of spinal cord. Normal body stores are sufficient to last for 3-6 years. Sources of Vitamin B12 are liver, shellfish, fish, meat, eggs, milk, cheese & yogurt.

## **Decreased Levels**

- Lack of Intrinsic factor: Total or partial gastrectomy, Atrophic gastritis, Intrinsic factor antibodies
- Malabsorption: Regional ileitis, resected bowel, Tropical Sprue, Celiac disease, pancreatic insufficiency, bacterial overgrowth & achlorhydria
- Loss of ingested vitamin B12: fish tapeworm
- · Dietary deficiency: Vegetarians
- Congenital disorders: Orotic aciduria & transcobalamine deficiency
- Increased demand: Pregnancy specially last trimester

## **Increased Levels**

Chronic renal failure, Congestive heart failure, Acute & Chronic Myeloid Leukemia, Polycythemia vera, Carcinomas with liver metastasis, Liver disease, Drug induced cholestasis & Protein malnutrition

\* Not in NABL scope



Page 10 of 12



283280071

Name : Mr. DAVINDER

Age: 50 Years

Ref By: Dr. SELF

Collected
Received
Male

: 30/6/2020 8:15:00AM

Received : 30/6/2020 11:39:35AM Reported : 30/6/2020 5:36:27PM

Report Status : Final

Test NameResultsUnitsBio. Ref. IntervalVITAMIN D, 25 - HYDROXY, SERUM \*57.03nmol/L75.00 - 250.00

Gender:

(ECLIA)

Lab No.

A/c Status

#### Interpretation

LEVEL	REFERENCE RANGE   IN nmol/L	COMMENTS
Deficient	< 50 	High risk for developing   bone disease
Insufficient       	   50-74   	Vitamin D concentration     Which normalizes   Parathyroid hormone   concentration
Sufficient	75-250 	Optimal concentration for maximal health benefit
Potential   intoxication	>250 	   High risk for toxic   effects

## Note

- The assay measures both D2 (Ergocalciferol) and D3 (Cholecalciferol) metabolites of vitamin D.
- 25 (OH)D is influenced by sunlight, latitude, skin pigmentation, sunscreen use and hepatic function.
- Optimal calcium absorption requires vitamin D 25 (OH) levels exceeding 75 nmol/L.
- It shows seasonal variation, with values being 40-50% lower in winter than in summer.
- Levels vary with age and are increased in pregnancy.
- A new test Vitamin D, Ultrasensitive by LC-MS/MS is also available

## Comments

Vitamin D promotes absorption of calcium and phosphorus and mineralization of bones and teeth. Deficiency in children causes Rickets and in adults leads to Osteomalacia. It can also lead to Hypocalcemia and Tetany. Vitamin D status is best determined by measurement of 25 hydroxy vitamin D, as it is the major circulating form and has longer half life (2-3 weeks) than 1,25 Dihydroxy vitamin D (5-8 hrs).

#### **Decreased Levels**

\* Not in NABL scope



Page 11 of 12



Name : Mr. DAVINDER

Lab No.

A/c Status

: 283280071 Age: 50 Years

Ref By: Dr. SELF

Gender: Male

Received Reported

30/6/2020 8:15:00AM

: 30/6/2020 11:39:35AM : 30/6/2020 5:36:27PM

Report Status : Final

Test Name Results Units Bio. Ref. Interval

Inadequate exposure to sunlight

Dietary deficiency

Vitamin D malabsorption

· Severe Hepatocellular disease

Drugs like Anticonvulsants

• Nephrotic syndrome

#### Increased levels

Vitamin D intoxication

Dr Pritika Uniyal MD, Pathology Chief of Lab

-----End of report -----

## **IMPORTANT INSTRUCTIONS**

\*Test results released pertain to the specimen submitted.\*All test results are dependent on the quality of the sample received by the Laboratory.

\*Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician.\*Sample repeats are accepted on request of Referring Physician within 7 days post reporting.\*Report delivery may be delayed due to unforeseen circumstances. Inconvenience is regretted.\*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit request within 72 hours post reporting.\*Test results may show interlaboratory variations.\*The Courts/Forum at Delhi shall have exclusive jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).\*Test results are not valid for medico legal purposes. \*Contact customer care Tel No. +91-11-39885050 for all queries related to test results.

(#) Sample drawn from outside source.

\* Not in NABL scope



Page 12 of 12